- Home
- GFR vs KROS Comparison
GFR vs KROS Comparison
Compare GFR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFR
- KROS
- Stock Information
- Founded
- GFR 2018
- KROS 2015
- Country
- GFR Canada
- KROS United States
- Employees
- GFR N/A
- KROS N/A
- Industry
- GFR
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- GFR
- KROS Health Care
- Exchange
- GFR Nasdaq
- KROS Nasdaq
- Market Cap
- GFR 519.2M
- KROS 460.6M
- IPO Year
- GFR N/A
- KROS 2020
- Fundamental
- Price
- GFR $6.38
- KROS $11.02
- Analyst Decision
- GFR Buy
- KROS Buy
- Analyst Count
- GFR 1
- KROS 11
- Target Price
- GFR $10.50
- KROS $45.33
- AVG Volume (30 Days)
- GFR 62.3K
- KROS 1.0M
- Earning Date
- GFR 03-04-2025
- KROS 03-03-2025
- Dividend Yield
- GFR N/A
- KROS N/A
- EPS Growth
- GFR N/A
- KROS N/A
- EPS
- GFR 0.40
- KROS N/A
- Revenue
- GFR $551,353,492.00
- KROS $651,000.00
- Revenue This Year
- GFR $35.03
- KROS $303.27
- Revenue Next Year
- GFR $37.50
- KROS N/A
- P/E Ratio
- GFR $15.94
- KROS N/A
- Revenue Growth
- GFR 11.20
- KROS 8037.50
- 52 Week Low
- GFR $4.68
- KROS $9.78
- 52 Week High
- GFR $8.16
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- GFR 37.04
- KROS 33.50
- Support Level
- GFR $6.40
- KROS $10.09
- Resistance Level
- GFR $6.67
- KROS $12.05
- Average True Range (ATR)
- GFR 0.19
- KROS 0.44
- MACD
- GFR 0.01
- KROS 0.73
- Stochastic Oscillator
- GFR 36.96
- KROS 47.45
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.